Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.

Abstract

Glycopyrronium bromide is a new long-acting muscarinic antagonist to be used once-daily, which is approved as a bronchodilator for the symptomatic maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD). In the Glycopyrronium bromide in chronic Obstructive pulmonary disease airWays trials, treatment with inhaled glycopyrronium bromide at 50 μg once daily achieved a significantly better lung function than placebo, as measured by the trough forced expiratory volume in 1 s in patients with moderate-to-severe COPD. The lung function improvement was maintained for up to 52 weeks. Other improved indexes were dyspnea scores, health status, exacerbation rates and time of exercise endurance. Studies comparing the efficacy of glycopyrronium versus tiotropium bromide found substantial equivalence of the two drugs. Glycopyrronium was generally well tolerated. These data add inhaled glycopyrronium bromide to the treatment of patients with moderate to severe COPD as an effective once-daily LAMA.

• Authors: Gian Galeazzo Riario-Sforza, Erminia Ridolo, Edoardo Riario-Sforza, Cristoforo Incorvaia
• Journal: Expert review of respiratory medicine (Expert Rev Respir Med) Vol. 9 Issue 1 Pg. 23-33 (Feb 2015) ISSN: 1747-6356 [Electronic] England
• PMID: 25547422 (Publication Type: Journal Article, Review)

Chemical References

• Bronchodilator Agents
• Muscarinic Antagonists
• Glycopyrrolate

Topics

• Bronchodilator Agents (administration & dosage, adverse effects, therapeutic use)
• Drug Administration Schedule
• Glycopyrrolate (administration & dosage, adverse effects, therapeutic use)
• Humans
• Lung (drug effects, physiopathology)
• Muscarinic Antagonists (administration & dosage, adverse effects, therapeutic use)
• Pulmonary Disease, Chronic Obstructive (diagnosis, drug therapy, physiopathology)
• Recovery of Function
• Severity of Illness Index
• Treatment Outcome